Link Cell Therapies Secures $30 Million in Series A Extension

Link Cell Therapies Secures $30 Million in Series A Extension

Link Cell Therapies, a biotech company based in San Francisco, California, has successfully raised $30 million in a Series A Extension funding round. The company focuses on developing innovative cell therapy solutions aimed at treating various diseases.

Investors

The Series A Extension round attracted investments from several notable entities, including BMS, Kyowa Kirin, Sherpa Healthcare Partners, Western Technology Investment, and the MD Anderson Cancer Focus Fund. The diversity of investors underscores the broad interest in Link Cell Therapies’ potential to make significant strides in the field of cell therapies.

Use of Funds

While specific details on the use of these funds have not been disclosed, it is anticipated that the capital will be directed towards advancing Link Cell Therapies' research and development efforts, expanding its team, and potentially accelerating clinical trials for its therapeutic candidates.

Location

Link Cell Therapies operates out of San Francisco, California, United States, a hub for biotechnology and life sciences companies. This strategic location offers the company access to a vibrant ecosystem of research institutions and industry partners.

Company Overview

Link Cell Therapies is dedicated to advancing cell-based therapies to address unmet medical needs. By leveraging cutting-edge research, the company is working to develop innovative treatments that could transform the landscape of healthcare.